In early June, the first case of monkeypox (now known as MPX) was identified in San Francisco, and as of September 3, 2022, a total of 740 cases have been identified in SF. The current MPX outbreak is predominantly occurring among men who have sex with men (MSM) and trans people who have sex with men and is disproportionately affecting people living with HIV. This is believed to be related to transmission via close and/or intimate contacts within sexual and social networks. MPX symptoms can mimic symptoms of common STIs including syphilis and herpes. HIV and STI testing should be routinely offered to persons evaluated for MPX, with linkage to HIV care or HIV preexposure prophylaxis (PrEP) as appropriate.

On September 6, 2022, SFDPH expanded vaccine eligibility criteria to include all gay or bisexual men, and all men or trans people who have sex with men or trans people. In addition, SFDPH and other Bay Area counties are now offering 2nd doses to those who are ≥ 28 days from their first dose. For additional information, visit MPX Vaccine | San Francisco (sf.gov).

See the latest SFDPH MPX Health Update 8/10/22 that provides guidance for SF providers including:
- Initial evaluation, testing, and specimen collection
- Infection control precautions
- Updated eligibility for the monkeypox vaccine (Jynneos)
  - See August 18th health advisory with recommendation for intradermal (ID) vaccine administration
- Patient educational materials

You can continue to find updated monkeypox guidance for SF providers at www.sfcdcp.org/monkeypoxHCP. New helpful resources include a Provider Tip Sheet and MPX Update for Clinicians webinar (recording/slides).

Increasing MPX Cases in San Francisco

In early June, the first case of monkeypox (now known as MPX) was identified in San Francisco, and as of September 3, 2022, a total of 740 cases have been identified in SF. The current MPX outbreak is predominantly occurring among men who have sex with men (MSM) and trans people who have sex with men and is disproportionately affecting people living with HIV. This is believed to be related to transmission via close and/or intimate contacts within sexual and social networks. MPX symptoms can mimic symptoms of common STIs including syphilis and herpes. HIV and STI testing should be routinely offered to persons evaluated for MPX, with linkage to HIV care or HIV preexposure prophylaxis (PrEP) as appropriate.

On September 6, 2022, SFDPH expanded vaccine eligibility criteria to include all gay or bisexual men, and all men or trans people who have sex with men or trans people. In addition, SFDPH and other Bay Area counties are now offering 2nd doses to those who are ≥ 28 days from their first dose. For additional information, visit MPX Vaccine | San Francisco (sf.gov).

See the latest SFDPH MPX Health Update 8/10/22 that provides guidance for SF providers including:
- Initial evaluation, testing, and specimen collection
- Infection control precautions
- Updated eligibility for the monkeypox vaccine (Jynneos)
  - See August 18th health advisory with recommendation for intradermal (ID) vaccine administration
- Patient educational materials

You can continue to find updated monkeypox guidance for SF providers at www.sfcdcp.org/monkeypoxHCP. New helpful resources include a Provider Tip Sheet and MPX Update for Clinicians webinar (recording/slides).

Provider STI Reporting: 628-217-6653, 628-217-6603 (fax)